Browse

Arginine methylation: the promise of a ‘silver bullet’ for brain tumours? (2021)
Journal Article
Samuel, S. F., Samuel, S. F., Barry, A., Greenman, J., & Beltran-Alvarez, P. (in press). Arginine methylation: the promise of a ‘silver bullet’ for brain tumours?. Amino acids, https://doi.org/10.1007/s00726-020-02937-x

Despite intense research efforts, our pharmaceutical repertoire against high-grade brain tumours has not been able to increase patient survival for a decade and life expectancy remains at less than 16 months after diagnosis, on average. Inhibitors of... Read More about Arginine methylation: the promise of a ‘silver bullet’ for brain tumours?.

The inhibitory subunit of cardiac troponin (cTnI) is modified by arginine methylation in the human heart (2019)
Journal Article
Onwuli, D. O., Samuel, S., Sfyri, P., Welham, K., Goddard, M., Abu-Omar, Y., …Beltran-Alvarez, P. (2019). The inhibitory subunit of cardiac troponin (cTnI) is modified by arginine methylation in the human heart. International journal of cardiology, 282, 76-80. https://doi.org/10.1016/j.ijcard.2019.01.102

Background The inhibitory subunit of cardiac troponin (cTnI) is a gold standard cardiac biomarker and also an essential protein in cardiomyocyte excitation-contraction coupling. The interactions of cTnI with other proteins are fine-tuned by post-tra... Read More about The inhibitory subunit of cardiac troponin (cTnI) is modified by arginine methylation in the human heart.

Inhibiting arginine methylation as a tool to investigate cross-talk with methylation and acetylation post-translational modifications in a glioblastoma cell line (2018)
Journal Article
Samuel, S. F., Marsden, A. J., Deepak, S., Rivero, F., Greenman, J., & Beltran-Alvarez, P. (2018). Inhibiting arginine methylation as a tool to investigate cross-talk with methylation and acetylation post-translational modifications in a glioblastoma cell line. Proteomes, 6(4), https://doi.org/10.3390/proteomes6040044

Glioblastomas (GBM) are the most common grade 4 brain tumours; patients have very poor prognosis with an average survival of 15 months after diagnosis. Novel research lines have begun to explore aberrant protein arginine methylation (ArgMe) as a poss... Read More about Inhibiting arginine methylation as a tool to investigate cross-talk with methylation and acetylation post-translational modifications in a glioblastoma cell line.